avapro has been researched along with Chronic Disease in 16 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 6.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| "Patients treated with amiodarone plus irbesartan had a lower rate of recurrence of atrial fibrillation than did patients treated with amiodarone alone." | 5.10 | Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. ( Bernal, E; Bueno, MG; Cabeza, P; Cano, JM; Cano, L; Madrid, AH; Marín, I; Moro, C; Peña, G; Rebollo, JM; Rodriguez, A, 2002) |
| "In children with chronic kidney disease the effects of the angiotensin II antagonist irbesartan on arterial pressure and proteinuria mimic those observed with the converting enzyme inhibitors." | 5.09 | Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. ( Bianchetti, MG; Teuffel, O; von Vigier, RO; Zberg, PM, 2000) |
| " In group A, 8 weeks of treatment induced a two- to nine-fold reduction in urinary cytokine levels (GCSF, GM-CSF, IFN-γ, IL-1a, IL-11, IL-12p40, MCP-2, MIP-1a), while increasing the dosage to 300 mg/d further decreased the excretion of GCSF, GM-CSF, IL-12p40, MCP-2 and MIP-1a by week 18." | 2.77 | Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease. ( Huang, HQ; Liu, BC; Lü, LL; Ni, J; Zheng, M, 2012) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 2.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Zhang, L | 1 |
| Zhai, R | 1 |
| Lan, J | 1 |
| Nijiati, Y | 1 |
| Yang, T | 1 |
| Aimaiti, M | 1 |
| Maimaitiyiming, D | 1 |
| Aikemu, A | 1 |
| Desai, RJ | 1 |
| Ashton, CM | 1 |
| Deswal, A | 1 |
| Morgan, RO | 1 |
| Mehta, HB | 1 |
| Chen, H | 1 |
| Aparasu, RR | 1 |
| Johnson, ML | 1 |
| Ni, J | 1 |
| Huang, HQ | 1 |
| Lü, LL | 1 |
| Zheng, M | 1 |
| Liu, BC | 1 |
| Tsuruoka, S | 1 |
| Kai, H | 1 |
| Usui, J | 1 |
| Morito, N | 1 |
| Saito, C | 1 |
| Yoh, K | 1 |
| Yamagata, K | 1 |
| Madrid, AH | 1 |
| Bueno, MG | 1 |
| Rebollo, JM | 1 |
| Marín, I | 1 |
| Peña, G | 1 |
| Bernal, E | 1 |
| Rodriguez, A | 1 |
| Cano, L | 1 |
| Cano, JM | 1 |
| Cabeza, P | 1 |
| Moro, C | 1 |
| Haneda, M | 1 |
| Lods, N | 1 |
| Ferrari, P | 1 |
| Frey, FJ | 1 |
| Kappeler, A | 1 |
| Berthier, C | 1 |
| Vogt, B | 1 |
| Marti, HP | 1 |
| Falcão, LM | 1 |
| Pinto, F | 1 |
| Ravara, L | 1 |
| van Zwieten, PA | 1 |
| Höcht, C | 1 |
| Opezzo, JA | 1 |
| Taira, CA | 1 |
| Tu, X | 1 |
| Chen, X | 1 |
| Xie, Y | 1 |
| Shi, S | 1 |
| Wang, J | 1 |
| Chen, Y | 1 |
| Li, J | 1 |
| Willenheimer, R | 1 |
| von Vigier, RO | 1 |
| Zberg, PM | 1 |
| Teuffel, O | 1 |
| Bianchetti, MG | 1 |
| Upnitskiĭ, AA | 1 |
| Khanina, NIu | 1 |
| Belousov, IuB | 1 |
| McDonald, JE | 1 |
| Padmanabhan, N | 1 |
| Petrie, MC | 1 |
| Hillier, C | 1 |
| Connell, JM | 1 |
| McMurray, JJ | 1 |
| Würzner, G | 1 |
| Gerster, JC | 1 |
| Chiolero, A | 1 |
| Maillard, M | 1 |
| Fallab-Stubi, CL | 1 |
| Brunner, HR | 1 |
| Burnier, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.[NCT02582190] | Phase 3 | 0 participants (Actual) | Interventional | 2017-12-02 | Withdrawn (stopped due to Investigational Medicinal Product Supplies) | ||
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for avapro and Chronic Disease
| Article | Year |
|---|---|
[Diabetic nephropathy].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2002 |
8 trials available for avapro and Chronic Disease
| Article | Year |
|---|---|
Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Creatinine; Cross-Over | 2012 |
Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Biphe | 2013 |
Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
Topics: Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl C | 2003 |
BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Natr | 2004 |
Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
Topics: Adolescent; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2000 |
Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.
Topics: Administration, Oral; Angina Pectoris; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonis | 2001 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind | 2001 |
7 other studies available for avapro and Chronic Disease
| Article | Year |
|---|---|
Comparison of Irbesartan and Benazepril Hydrochloride on Urine Protein Reduction in Chronic Glomerulonephritis.
Topics: Benzazepines; Chronic Disease; Glomerulonephritis; Humans; Irbesartan | 2020 |
Irbesartan ameliorates chronic mountain sickness in a rat model via the cholesterol metabolism: An iTRAQ -based proteomics analysis.
Topics: Altitude Sickness; Animals; Antihypertensive Agents; Cholesterol; Chronic Disease; Irbesartan; Prote | 2021 |
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confoun | 2012 |
Hypothalamic antihypertensive effect of irbesartan in chronic aortic coarctated rats.
Topics: Animals; Antihypertensive Agents; Aortic Coarctation; Biphenyl Compounds; Chronic Disease; Female; H | 2005 |
Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biphenyl Compounds; Blood | 2008 |
Comment on "Effects of long-term angiotensin II AT-1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats".
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1999 |
[Choosing the dose of aprovel (irbesartan) in patients with chronic heart insufficiency].
Topics: Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Dose-Response Relatio | 2001 |